España
Umbral anuncia la iniciación de la dosificación con TH-302/Bortezomib Velcade / dexametasona "TBorD" en la etapa final de curso de la Fase 1/2 Prueba de pacientes con recaída / mieloma múltiple refractario
... no acaba de xplotar como otras eh !!
https://www.google.com/finance?q=NYSE%3APBYI&ei=hq3PU6j7GOmIwAOU8IHgDw
Puma Biotechnology Inc
(NYSE:PBYI) 229.69
+170.66 (+289.11%)
Esto es del dia 14 pasado, lo he visto ahora.
3. Threshold Pharmaceuticals (Nasdaq: THLD)
View gallery
.
I have been following this biotech firm for several years, acknowledging all the while that investors would need to show patience during the long and arduous phases of clinical trial testing.
Well, the wait is almost over.
Threshold's TH-302, which focuses on oxygen-deprived tumors that are hard to treat with traditional chemotherapy drugs. Though the company is testing a wide range of tumors in Phase I and II clinical trials, it is also conducting Phase III trials for soft tissue sarcoma and pancreatic cancer.
The primary data collection phase for the soft tissue sarcoma trial nearing completion (ClinicalTrials.gov says it was scheduled to be completed in June). Although Threshold won't provide a complete set of analysis to the FDA until next winter, it is expected to release a preliminary look at the data in coming months.
Positive results could send this stock far higher, in part because it would serve as an endorsement for all of the TH-302 earlier-stage trials.
[More from StreetAuthority.com: 6 Stocks With Major Insider Buying]
Risks to Consider: Even armed with solid clinical trial data, some drugs just don't pass muster with the FDA, so no drug is a sure thing, until it is approved.
Action to Take --> Biotech and medtech catalysts often stare investors right in the face, yet still get ignored. I greatly prefer focusing on companies with drugs or devices in Phase II or Phase III trials, simply because earlier-stage trials often end up yielding poor results. These three stocks are poised to deliver solid catalysts in 2014, making this a good time to listen to their imminent quarterly conference calls.
http://finance.yahoo.com/news/3-health-care-stocks-primed-150000250.html
Hoy al cierre ( supongo ), tendremos el report Q2. El EPS estimado por los analistas es de -0,13$.
Como nos tiene acostumbrada la muy jodida, bajará después de la publicación de resultadosl
.... hubo alguna novedad o publicación ayer ??? .... no veo nada nuevo.
no .., todavia nada
